Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
NCT07203287
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Post Operative Pulmonary Complications
- Neuromuscular Blockade
- General Anesthesia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- The University of Texas Medical Branch, Galveston
- Last updated on ClinicalTrials.gov
- February 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- University of Texas Medical Branch · Galveston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.